• It's Coming...

    MARKET EDGES

    Identify global risks and opportunities with essential macro intel using Hedgeye’s Market Edges.

We took Wall Street analysts to task last week for suggesting beleaguered Valeant Pharmaceuticals (VRX) shares still had 150% upside. Sadly, not much has changed.

CLICK IMAGE TO ENLARGE.

This One Picture (Still) Captures Everything Wrong With Wall Street (Nothing's Changed) | $VRX - VRX consensus update

VRX is trading around $74. Shares are down almost 72% from its August high. Here's the current breakdown of the 25 Wall Street analysts covering the stock:

  • 65% currently rate VRX a Buy (unchanged from last week)
  • The average analyst price target is $180 (versus $199)
  • That implies approximately 144% upside (down from 150%)

*Sad*

To be clear, the negativity surrounding Valeant is worse today than it was when last we checked in on Old Wall. Concerns about insider selling, no update from management on VRX's longer-term outlook, and the legal question mark surrounding its partnership with pharmacy Philidor loom large over the stock. 

Hedgeye's Healthcare analysts released a research note to institutional subscribers last week outlining why we think shares are worth $20. To be clear, we’ve long been skeptical.

CLICK HERE to read their original Short thesis on VRX from 7/22/14.